ArticleMolecular biology reports2024
Exploring the purification, characterization, and industrial applications of Exopolysaccharide (EPS) from Bacillus amyloliquefaciens strain BDIFST240014.
Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Characterization of Plant Growth-Promoting Bacteria Associated withMicroorganisms · 2026Article
- Process optimization ofFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExopolysaccharides (EPS) derived from microbial sources hold great promise for various industrial applications due to their biodegradability and diverse biological activities. METHODS AND
resultsIn this study, EPS was isolated and characterized from Bacillus amyloliquefaciens strain BDIFST240014, a Gram-positive bacterium known for its robust EPS production. Taxonomic classification was confirmed through 16 S rRNA gene sequencing. We optimized the growth conditions for EPS production, yielding a maximum of approximately 74.81 mg/L after 48 h of incubation at 37 °C. UV-vis and FTIR spectroscopy were used to characterize the EPS, revealing key functional groups indicative of its polysaccharide nature. The EPS contained total carbohydrate and protein contents of 841.234 µg/5 mg and 630.54 µg/5 mg, respectively, along with a potent water holding capacity (WHC) of 103.31% and oil holding capacity (OHC) of 106.78%, underscoring its potential as a multifunctional biopolymer. Antimicrobial assays demonstrated significant activity against both Gram positive and Gram negative pathogens, including S. aureus, B. subtilis, E. coli, and S. typhi. Antioxidant assays confirmed its potent DPPH radical scavenging activity (71.52%) and Fe³⁺ reducing capacity. Furthermore, emulsification studies showed its efficacy with various oils (coconut oil, soybean oil, sunflower oil, olive oil) and a hydrocarbon (n-hexane), with the highest emulsification indices (E1 and E24) of 60.78% and 60.39%, respectively, against coconut and sunflower oils. Notably, the EPS selectively promoted the growth of probiotic strains while not enhancing the growth of pathogenic bacteria, highlighting its prebiotic potential.
conclusionsThese findings suggest that EPS from B. amyloliquefaciens BDIFST240014 is a promising candidate for diverse industrial and biomedical applications.
Indexed as
Identifiers
39680227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.